Tobramycin powder is an aminoglycoside antibiotic which interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, resulting in a defective bacterial cell membrane.

**Authorization Criteria:** management of cystic fibrosis patients with *Pseudomonas aeruginosa* in patients six years of age or older

**Dosing:** inhalation of the contents of four 28 mg TOBI capsules twice-daily for 28 days using the Podhaler device.

**How Supplied:** 28 mg capsules

**Contraindications/Warnings:** FOR USE WITH THE PODHALER DEVICE ONLY; contraindicated with a known hypersensitivity to any aminoglycoside; use with caution in patients with renal, auditory, vestibular dysfunction or neuromuscular disorders; may cause bronchospasm

**Major Adverse Reactions:** cough; dyspnea; oropharyngeal pain

**Major Drug Interactions:** diuretics may enhance potential toxicity

**REFERENCES**


Revision History:

Date Approved by P&T Committee: 4/22/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 01.27.15
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/Archived: 1/1/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates/Date Unarchived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/1/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Archived – excluded from the Formulary effective 1/1/18</td>
</tr>
<tr>
<td>1/22/19</td>
<td>Yes</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Unarchived – Formulary Exclusion – For Exception Review Use Only Annual Review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>